Article
RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Leukemia - 1 Apr 2018
Jerchel I S, Hoogkamer A Q, Ariës I M, Steeghs E M P, Boer J M, Besselink N J M, Boeree A, van de Ven C, de Groot-Kruseman H A, de Haas V, Horstmann M A, Escherich G, Zwaan C M, Cuppen E, Koudijs M J, Pieters R, den Boer M L
Abstract excerpt
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defined subgroups using highly sensitive and quantitative methods are lacking. Targeted deep sequencing of 13 RAS pathway genes was performed in 461 pediatric BCP-ALL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.